Last reviewed · How we verify
NCT04405713: ACC
Different Timing for Early Laparoscopic Cholecystectomy in Acute Calcular Cholecystitis
NA trial testing from the onset of symptoms within the first 3 days in Acute Cholecystitis in 900 participants. Completed in 25 March 2020.
1 March 2020
Quick facts
| Lead sponsor | Mansoura University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 900 |
| Start date | 1 April 2018 |
| Primary completion | 1 March 2020 |
| Estimated completion | 25 March 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- from the onset of symptoms within the first 3 days
- : from the onset of symptoms within the 4-7 days
- from the onset of symptoms beyond 7 days
Conditions studied
- Acute Cholecystitis — all drugs for Acute Cholecystitis →
Sponsor
Mansoura University
Who can join
Eligibility, any sex, with Acute Cholecystitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ideal timing for ELC continues to be debatable in patients with acute calculator cholecystitis (ACC). This study was planned to identify the impact of different ELC timing in ACC on surgical outcomes in terms of safety and efficacy
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04405713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Cholecystitis
Currently open trials in the same condition.
- NCT07161960 — Early Versus Delayed Cholecystectomy After Percutaneous Cholecystostomy in Moderate and Severe Cholecystitis (ESCAPE) · NA · recruiting
- NCT06967597 — Conservative Versus Proactive Management of Acute Cholecystitis After EUS-guided Transmural Gallbladder Drainage: FUGITI · NA · recruiting
- NCT07006298 — One-year Outcomes by Index Treatment in Elderly Patients With Acute Cholecystitis · recruiting
- NCT06287112 — Prevention of Acute Cholecystitis With ETGBD · NA · recruiting
- NCT05732480 — Influence of Gut Microbiome in Gallstone Disease · recruiting
Other Mansoura University trials
Trials by the same sponsor.
- NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
- NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
- NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
- NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04405713 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mansoura University
- Last refreshed: 28 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04405713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing